Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BPTF | Q12830 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20121992 | 0.98 | MEN1 (0.55) | MEN1KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL20121989 | 0.98 | MEN1 (0.55) | MEN1KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9944480 | 0.98 | MEN1 (0.55) | MEN1KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL23080297 | 0.98 | MEN1 (0.55) | MEN1KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1515195 | 0.95 | MEN1 (0.47) | MEN1KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL23518518 | 0.90 | ALDH1A1 (0.42) | MEN1KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2677304 | 0.86 | KMT2A (0.41) | MEN1KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL8487332 | 0.84 | ATM (0.48) | MEN1KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL8487327 | 0.84 | ATM (0.48) | MEN1KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL12384375 | 0.82 | L3MBTL1 (0.47) | MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018015-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| WO-2023215354-A1 | MENIN PROTEOLYSIS TARGETING CHIMERAS (PROTACS) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-11759455-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-19 | — | — | US | disclosed |
| US-11759455-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-19 | — | — | US | disclosed |
| US-20230277551-A1 | ANTIBACTERIAL CHEMICAL COMPOUND, ITS MANUFACTURING METHOD AND ITS USE THEREOF | NATIONAL YANG MING CHIAO TUNG UNIVERSITY (TW) | 2023-09-07 | — | — | US | disclosed |
| US-7582775-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7566803-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090018058-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (US) | 2009-01-15 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| EP-1687292-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070149810-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018058-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | MEN1 4536/4885KMT2A 4153/4885CYP1A2 622/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | MEN1 1860/4885KMT2A 33/4885CYP1A2 4665/4885 |
| US-12018015-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | MEN1 1615/4885KMT2A 2794/4885CYP1A2 3563/4885 |
| US-20080200552-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | MEN1 2203/4885KMT2A 4024/4885CYP1A2 1057/4885 |
| US-20070106095-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | MEN1 3024/4885KMT2A 4279/4885CYP1A2 1058/4885 |
| US-20070149810-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | MEN1 3208/4885KMT2A 3802/4885CYP1A2 1035/4885 |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | AURKA, AURKB, AURKC | MEN1 1380/4885KMT2A 622/4885CYP1A2 2568/4885 |
| US-20230277551-A1 | ANTIBACTERIAL CHEMICAL COMPOUND, ITS MANUFACTURING METHOD AND ITS USE THEREOF | VIP, MRPL21, GSDMD | MEN1 2902/4885KMT2A 3152/4885CYP1A2 1417/4885 |
| US-11759455-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | MEN1 4756/4885KMT2A 1534/4885CYP1A2 716/4885 |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | MEN1 3832/4885KMT2A 37/4885CYP1A2 2939/4885 |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | MEN1 4756/4885KMT2A 1534/4885CYP1A2 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.